71130-06-8

Basic information

• Product Name: Ranitidine hydrochloride
• Synonyms: [(Dimethylamino)methyl]furfuryl]thio]ethyl]-N'-methyl-2-nitrovinylidenediamine monohydrochloride;RANITIDINE (ranitidine);-N-(2-(((5-((Dimethylamino);-N-methyl-2-nitroethene-1,1-diamine;ZANTAC;RANITIDINE HCL;N-[2-[[[5-[(DIMETHYLAMINO)METHYL]-2-FURANYL]METHYL]THIO]ETHYL]-N'-METHYL-2-NITRO-1,1-ETHANEDIAMINE HYDROCHLORIDE;N-[2-[[[-5-[(DIMETHYLAMINO)METHYL]-2-FURANYL]METHYL]THIO]ETHYL]-N'-METHYL-2-NITRO-1,1 ETHENEDIAMINE, HYDROCHLORIDE
• CAS NO: 71130-06-8
• Molecular Formula: C₁₃H₂₂N₄O₃S*ClH
• Molecular Weight: 350.86
• EINECS: 275-207-4
• Product Categories: API;Miscellaneous;Histamine receptor
• Mol File: 71130-06-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 437.1 °C at 760 mmHg
• Flash Point: 218.2 °C
• Appearance: tan/solid
• Solubility: H2O: 1.8 mg/mL
• CAS DataBase Reference: Ranitidine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Ranitidine hydrochloride(71130-06-8)
• EPA Substance Registry System: Ranitidine hydrochloride(71130-06-8)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 2
• RTECS: KM6557000
• Hazardous Substances Data: 71130-06-8(Hazardous Substances Data)

Usage

Uses

A histamine H2-receptor antagonist

Veterinary Drugs and Treatments

In veterinary medicine, ranitidine has been used for the treatment and/or prophylaxis of gastric, abomasal, and duodenal ulcers, uremic gastritis, stress-related or drug-induced erosive gastritis, esophagitis, duodenal gastric reflux and esophageal reflux. It has also been employed to treat hypersecretory conditions associated with gastrinomas and systemic mastocytosis. Because of its effects on gastric motility, ranitidine may be useful in increasing gastric emptying, particularly when delayed gastric emptying is associated with gastric ulcer disease. Ranitidine may also be useful to stimulate colonic activity in cats via its prokinetic effects.

InChI:InChI=1/C12H20N4O3S.ClH/c1-13-11(8-16(17)18)14-6-7-20-9-10-4-5-12(19-10)15(2)3;/h4-5,8,13-14H,6-7,9H2,1-3H3;1H/b11-8+;

Upstream product

• 66357-35-5 ranitidine 
• 102721-76-6 2-methylamino-2-methylthio-1-nitroethene 
• 66356-53-4 5-{[(2-aminoethyl)thio]methyl}-N,N-dimethyl-2-furfurylamine 
• 66357-35-5 Ranitidine 

Downstream Products

• 73857-20-2 C₁₃H₂₂N₄O₄S 
• 73851-70-4 Ranitidine S-oxide 
• 72078-82-1 N-methylnitroacetamide 
• 66356-53-4 5-{[(2-aminoethyl)thio]methyl}-N,N-dimethyl-2-furfurylamine 
• 74-89-5 methylamine 
• 81074-81-9 5-[(dimethylamino)methyl]-furfuryl alcohol hydrochloride 
• 15433-79-1 (5-dimethylaminomethyl-furan-2-yl)-methanol 
• 112233-24-6 3-methylamino-5,6-dihydro-2H-thiazin-2-one O-5-dimethylaminomethylfurfuryloxime 
• 112233-23-5 3-methylamino-5,6-dihydro-2H-1,4-thiazin-2-one oxime hydrochloride 
• 112233-25-7 N,N-dimethyl-5-(2(1-methylamino-2-(5-dimethylaminomethyl-2-furfuryl)-2-nitrovinylamino)ethyl-thiomethyl)furfurylamine 
• 148639-72-9 3-methylamino-5,6-dihydro-2H-1,4-thiazine-2-one oxime 

Relevant articles and documents

Preparation method of ranitidine hydrochloride with low NDMA content

The invention relates to the technical field of ranitidine hydrochloride preparation, in particular to a preparation method of ranitidine hydrochloride with low NDMA content, which comprises the following steps: adding a ranitidine base into ethanol, and stirring until complete dissloving is achieved; cooling the solution to -5 to 5 DEG C; controlling the temperature, adding a hydrochloric acid aqueous solution, adjusting the pH value to 4.5-6.5, and uniformly stirring; adding a seed crystal, preserving heat, stirring and crystallizing for 3-5 hours; and filtering a crystal, washing, drainingand drying to obtain the off-white crystal solid ranitidine hydrochloride. The salifying method disclosed by the invention has the advantages that the steps are simple, the raw material hydrochloric acid aqueous solution is easy to obtain, the product character is good, and the impurity content of the final product NDMA (N-Nitrosodimethylamine) is low.

Preparation of acid addition salts of amine bases by solid phase-gas phase reactions

A process for the preparation of an acid addition salt of an organic base comprising exposing the organic base in solid form to a gaseous acid, with the proviso that ziprasidone, its acid addition salts and intermediates thereof are excluded.

Aminoalkyl furan derivatives

Compounds of the general formula I: STR1 and physiologically acceptable salts thereof and N-oxides and hydrates, in which R1 and R2 which may be the same or different represent hydrogen, lower alkyl, cycloalkyl, lower alkenyl, aralkyl or lower alkyl interrupted by an oxygen atom or a group STR2 in which R4 represents hydrogen or lower alkyl or R1 and R2 may, together with the nitrogen atom to which they are attached, form a heterocyclic ring which may contain other heteroatoms selected from O and STR3 R3 is hydrogen, lower alkyl, lower alkenyl or alkoxyalkyl; X is --CH2 --, O or S; Y represents = S, = O, = NR5 or = CHR6 ; Alk denotes a straight or branched alkylene chain of 1 to 6 carbon atoms; R5 is H, nitro, cyano, lower alkyl, aryl, alkylsulphonyl, or arylsulphonyl; R6 represents nitro, arylsulphonyl or alkylsulphonyl; M is an integer from 2 to 4; and N is 1 or 2; or when X = S, or --CH2 --, n is zero, 1 or 2. These compounds have H2 -antagonist activity. Intermediates in the production thereof are also provided.